Investors Rekindle Interest in China's AI Pharma Sector, Though Tangible Results Are Yet to Come

Retrieved on: 2025-06-19 11:53:43

Tags for this article:

Insilico Medicine

Computational neuroscience

CSPC Pharmaceutical Group

Artificial intelligence

ChatGPT

AstraZeneca

Click the tags to see associated articles and topics

Investors Rekindle Interest in China's AI Pharma Sector, Though Tangible Results Are Yet to Come. View article details on hiswai:

Excerpt

These include a fundraiser by Boston-headquartered biotech firm Insilico Medicine and a new partnership between Shijiazhuang-based CSPC Pharmaceutical ...

Article found on: www.yicaiglobal.com

View Original Article